Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...
Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...
Pharmaceutical Technology on MSN2d
FDA awards ODD status to Sanofi’s rilzabrutinib for two rare conditionsSanofi's reversible BTK inhibitor rilzabrutinib has gained the US Food and Drug Administration’s (FDA) orphan drug ...
Sanofi’s treatment for hemophilia that can be administered as infrequently as once every other month, was approved by the US ...
Pharmaceutical Technology on MSN5d
Sanofi’s Qfitlia approved by FDA as first haemophilia therapy for all patientsDespite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper ...
The U.S. Food and Drug Administration has approved Sanofi's Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce ...
Zacks Investment Research on MSN1d
Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits FailureThis week, the FDA approved Sanofi’s SNY hemophilia therapy, fitusiran, Novartis’ NVS Vanrafia for the reduction of ...
Sanofi's rilzabrutinib receives FDA orphan drug designation for two rare diseases. Clinical studies show meaningful response ...
Sanofi's Qfitlia gains FDA approval, offering fewer injections in hemophilia care. Check out my recommendation for SNY stock.
The US Food and Drug Administration has approved fitusiran for bleeding prophylaxis in hemophilia A and B with or without ...
The latest development follows Sanofi's recent FDA approval for its haemophilia treatment, Qfitlia (fitusiran). "FDA awards ODD status to Sanofi’s rilzabrutinib for two rare conditions" was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback